The UK's High Court revoked Human Genome Sciences' patent on neutrokine-alpha, a protein involved in a number of inflammatory diseases, such as arthritis, asthma and chronic pulmonary disease, says the Financial Times. The judge ruled that HGS never said what the protein did or how it would function as a drug target in its initial application, according to the article, which also hints that HGS will have to scramble in its ongoing collaboration with GSK on a neutrokine-alpha drug for rheumatoid arthritis and lupus.
Proteins Don't Belong to Companies
Aug 01, 2008